FDA Clears First-To-Market Simultaneous Anesthetic Infusion and Wound Drainage Catheter System

In short

Vital 5, LLC, a VentureMD portfolio company, has received clearance from the U. S. FDA for ReLeaf™, a first-to-market, dual function catheter system that provides simultaneous anesthetic infusion and wound drainage.

Background

Continuous anesthetic infusion to the surgical site in the immediate post-operative period has been clinically proven to provide significant improvements to pain management. However this therapy is currently not compatible with the millions of surgical cases where a wound drain is prescribed.

By offering an integrated system that provides effective continuous local anaesthetic infusion while also providing an effective wound drain function, Vital 5 says its ReLeaf device will greatly expand the number of patients who can benefit from local anesthetic infusion therapy.

The clinical applications for the Vital 5 ReLeaf include any invasive surgical procedure, including spine, orthopedic, cardiothoracic, plastic, general, obstetrics and gynecological procedures.

VentureMD (venturemd.com) is an angel capital firm and medical device incubator focused on musculoskeletal products. The company provides financial, human and intellectual capital to start-up medical device companies. Focused on the orthopedic, spine, endoscopy and dental markets, the company partners with entrepreneurs, inventors, technology transfer offices and seed stage start-ups to launch and manage new medical device companies.

Source: Vital 5, LLC, Business Wire